Assess whether scientific advice should be sought before the next trial

Situation

Scientific advice should be sits with clinical-development physician because a pediatric ethicist objecting to the proposed design hit a 505(b)(2) program relying on literature plus a bridging study. Evidence is phase-3 protocol with endpoint-sensitivity issues; write the Pharma & Life Sciences Pharmacovigilance option that extract can carry.

Decision

Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• The population in phase-3 protocol with endpoint-sensitivity issues is the one a pediatric ethicist objecting to the proposed design named, so Proceed under protocol follows for this Pharmacovigilance file.
• The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the pathway is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a pediatric ethicist objecting to the proposed design before phase-3 protocol with endpoint-sensitivity issues arrived; no new Pharmacovigilance path.
• Provenance on phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim clinical-development physician would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read phase-3 protocol with endpoint-sensitivity issues against a pediatric ethicist objecting to the proposed design and write the one fact that would move scientific advice should be for clinical-development physician.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a pediatric ethicist objecting to the proposed design, then the two facts that force it, then the Monday action for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.